The authors report the planned definitive overall survival (OS) results from this joint analysis along with updates on the disease–free survival (DFS) end point. The addition of trastuzumab to paclitaxel after doxorubicin and cyclophosphamide in early–stage HER2–positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.

READ FULL ARTICLE Curated publisher From Mdlinx